Bryan Walsh is the Editorial Director at Vox.com. He focuses on the intersection of technology, climate change, and global issues, bringing insights from his work with the Future Perfect, tech, and world teams. Bryan's expertise has been featured in Axios, Yahoo News, Lexology, RealClearMarkets, and more.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Bryan Walsh's coverage spans a wide range of topics, including culture & society, scientific advancements, and technology. He frequently cites data and profiles key figures in his articles.
When pitching to Bryan, it’s essential to keep in mind the diverse themes he covers. Make sure your pitch aligns with either culture & society or scientific/tech developments. If you have access to relevant data that can support your pitch, this may increase its appeal.
Given the broad spectrum of topics covered by Bryan Walsh, it is crucial for pitches to be well-researched and tailored precisely to fit into one of his areas of interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The bill may be coming due for Silicon Valley’s huge investment in AI.
By: Komal Karnik Nigam, Deborah Cho, Bryan Walsh
The U.S. Food and Drug Administration (FDA) recently announced the establishment of a public docket to obtain information and comments to help FDA assess how best to advance the development of new biosimilar biological products. Specifically, FDA is seeking input on whether biosimilar product development would be best served by focusing on product class-specific guidance documents – that address common development issues that apply to a broad class of products – or by developing product-specific guidance documents, similar to the approach taken for generic small-molecule drugs.
By: Meredith Manning, Bryan Walsh, Michael N. Druckman
The U.S. Court of Appeals for the Ninth Circuit on Friday reversed the district court’s judgment in United States v. California Stem Cell Treatment Center, siding with the U.S. Food and Drug Administration (FDA) in finding that a stem cell clinic’s stromal vascular fraction (SVF) products may be regulated by the agency as new drugs. This ruling has significant implications for stem cell product manufacturers and distributors, as it aligns the Ninth Circuit with two others in agreement that SVF products require prior FDA approval before they may be sold commercially.
By: Komal Karnik Nigam, Deborah Cho, Bryan Walsh
U.S. President Biden signed a bill last Thursday postponing the sunset date of the rare pediatric disease Priority Review Voucher (PRV) program from September 30, 2024, to December 20, 2024. The bill, the “Continuing Appropriations and Extensions Act, 2025” is a temporary measure to continue the rare pediatric disease PRV program. There are currently other ongoing legislative efforts to renew the program through 2028 and later. We have summarized these proposals below.
By: Bryan Walsh, Hogan Lovells, Komal Karnik Nigam, Deborah Cho
U.S. President Biden signed a bill last Thursday postponing the sunset date of the rare pediatric disease Priority Review Voucher (PRV) program from...
The world really is getting better. So why don’t people believe it?
America voted for chaos — but we don’t know what real chaos is. Yet.
The “Oppenheimer” director built his career on making audiences confront humanity's darkest possibilities.
Welcome to our third annual celebration of the thinkers, innovators, and changemakers who are working to make the future a better place.
Thousands of people were convinced they were seeing drone swarms. Get used to it
(833) 317-6278 
